Here’s why NovoSeven® RT may be right for you.

Here’s why NovoSeven® RT may be right for you.

It’s effective. NovoSeven® RT is effective in controlling bleeding episodes, and preventing bleeds during surgery, in adults and children across 4 indicated disorders. And it’s a recombinant product, which minimizes the possibility of viral contamination.


It’s room temperature stable and travel ready. NovoSeven® RT requires no refrigeration. It should be stored between 36°F and 77°F. After mixing, you may keep it in the vial at these temperatures for up to 3 hours.a

aFor complete storage instructions, please see the Prescribing Information.


It’s quick to mix. With our MixPro® device, mixing a dose is as easy as attach, twist, and mix.


It's effective and fast to infuse. NovoSeven® RT is up to 18x faster to infuse than FEIBA for the treatment of bleeding episodes in patients with congenital hemophilia with inhibitors.b,c,d

bIndividual doses are compared and based on an 88-kg (194-lb) person receiving a single dose for a joint bleed (NovoSeven® RT: 90 mcg/kg; FEIBA: 70 U/kg).
cPatients are cautioned that the maximum injection or infusion rate of FEIBA must not exceed 2 units per kilogram of body weight per minute.
dInformation from FEIBA package insert.

It’s effective. NovoSeven® RT is effective in controlling bleeding episodes, and preventing bleeds during surgery, in adults and children across 4 indicated disorders. And it’s a recombinant product, which minimizes the possibility of viral contamination.


It’s room temperature stable and travel ready. NovoSeven® RT requires no refrigeration. It should be stored between 36°F and 77°F. After mixing, you may keep it in the vial at these temperatures for up to 3 hours.a

aFor complete storage instructions, please see the Prescribing Information.


It’s quick to mix. With our MixPro® device, mixing a dose is as easy as attach, twist, and mix.


It's effective and fast to infuse. NovoSeven® RT is up to 18x faster to infuse than FEIBA in patients with congenital homophilia.b,c,d  


bIndividual doses are compared and based on an 88-kg (194-lb) person receiving a single dose for a joint bleed (NovoSeven® RT: 90 mcg/kg; FEIBA: 70 U/kg).
cPatients are cautioned that the maximum injection or infusion rate of FEIBA must not exceed 2 units per kilogram of body weight per minute.
dInformation from FEIBA package insert.

Committed to leadership in hemophilia research and treatment.

NovoSeven® RT has a long history of helping people control their bleeds. Over 30 years of research is behind this treatment,d and today, we continue our commitment to finding new ways to help people with bleeding disorders.

d1988: expanded access began in the United States; 1999: FDA approval received.

Selected Important Safety Information

WARNING: BLOOD CLOTS

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported.
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function.
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT.

Indications and Usage

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is used for:

  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and people with Glanzmann’s thrombasthenia who have a decreased or absent response to platelet transfusions
  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information

WARNING: BLOOD CLOTS

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported.
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function.
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT.

Warnings and Precautions

  • NovoSeven® RT should be used with caution if you have an increased risk for blood clots, such as with disseminated intravascular coagulation (DIC), clogged arteries, crush injury, septicemia (an infection in the blood), uncontrolled bleeding after giving birth, history of heart disease, liver disease, limited movement following surgery, in elderly people, in newborns, or if you are taking aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates) with NovoSeven® RT.
  • Allergic reactions, including serious whole body allergic reactions, have been reported with NovoSeven® RT. Tell your healthcare provider if you are allergic to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. If you think you are having an allergic reaction, call your healthcare provider right away. Some signs of allergic reaction may include shortness of breath, rash, itching, redness of the skin, and fainting/dizziness.
  • People with Factor VII deficiency should be monitored by their healthcare provider for antibodies, which can cause NovoSeven® RT to stop working properly.

Side Effects

  • The most common and serious side effects are blood clots.
  • Tell your healthcare provider about any side effects that bother you or do not go away.

Use with Other Drugs

  • Blood clots may occur if NovoSeven® RT is given with Coagulation Factor XIII (13).

Please click here for Prescribing Information.

NovoSeven® RT is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.